Angiotensin-converting enzyme (ACE) inhibitors inhibit bradykinin degradation and can trigger oral-lingual angioedema in some patients (Carucci et al., 2020; Wilkerson and Winters, 2022). The gene discussed is ACE; the disease is angioedema.